Canadian high court upholds Sanofi's patent for Plavix

The Supreme Court of Canada voted 7-0 against a request from generic-drug maker Apotex to nullify Sanofi Synthelabo Canada's patent for Plavix, an anti-coagulant for treating cardiovascular degeneration. Apotex argued that Sanofi did not conduct original research to develop the medicine. The court said Sanofi showed due diligence in testing and identifying Plavix as an effective and nontoxic agent from a class of compounds that the company discovered and patented.

View Full Article in:

Globe and Mail (Toronto) (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Fort Worth, TX